Skip to main content

This translation is provided for general access and has no recorded medical-language review.

Editorial general information — not a clinical-review record

Published: Updated: Publisher: Dr. Murat Toktamışoğlu

Why is large-volume filler for body contouring a separate risk category?

Using a dermal filler designed for a facial indication in the buttocks, breasts, between muscles or for large-volume body enhancement is not the same indication. FDA states that no dermal filler or injectable silicone is approved for large-scale body contouring and warns of embolism, infection, tissue death, permanent disfigurement and death.

This translation has no recorded clinical or medical-language review.

Direct answer

  • Evidence for small facial volumes cannot be transferred to injections of hundreds of millilitres.
  • Vague terms such as liquid implant, biopolymer or permanent filler do not identify a product.
  • Complications may appear immediately or months to years after injection.

Indication and scale change together

Regulatory assessment concerns a particular product, volume range, anatomical area, age group and technique. Authorization for a facial fold or the back of the hand does not establish body safety. Large volume changes the scale of intravascular entry, migration, infectious burden, chronic inflammation and difficulty of surgical removal.

Injectable silicone is not an implant

A breast implant contains silicone within a shell; freely injected liquid silicone can migrate through tissue. Industrial or unidentified substances are not medical fillers. Injections from unlabeled containers in a hotel, home or nonmedical setting add hazards involving sterility, product verification and access to emergency care.

If exposure or symptoms have occurred

Shortness of breath, chest pain, sudden weakness, speech difficulty, severe headache or altered consciousness requires emergency help. Later pain, hardness, drainage, colour change or suspected migration warrants specialist assessment with the product name, amount, date, site and available records. Blind dissolution or removal should not be attempted before the material is identified.

Scope of this article

This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.

Sources and evidence limits

These links are editorial starting points used to examine the article's boundaries.

  1. Dermal Fillers (Soft Tissue Fillers)

    U.S. Food and Drug Administration (FDA) · 2023

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  2. Guideline for the Management of Hyaluronic Acid Filler-Induced Vascular Occlusion

    Gillian Murray, Cormac Convery, Lee Walker, Emma Davies; Complications in Medical Aesthetics Collaborative (CMAC) · 2021

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  3. Safety and Potential Complications of Facial Wrinkle Correction with Dermal Fillers: A Systematic Literature Review

    Audra Janovskiene, Deividas Chomicius, Dominykas Afanasjevas, Zygimantas Petronis, Dainius Razukevicius, Egle Jagelaviciene · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  4. Using Fat-Dissolving Injections That Are Not FDA Approved Can Be Harmful

    U.S. Food and Drug Administration · 2023

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  5. Efficacy, safety, and potential industry bias in using deoxycholic acid for submental fat reduction: a systematic review and meta-analysis of randomized clinical trials

    G. S. G. Inocêncio et al. · 2023

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  6. Management of Serious Adverse Events Following Deoxycholic Acid Injection for Submental and Jowl Fat Reduction: A Systematic Review and Management Recommendations

    S. M. Shridharani and M. L. Kennedy · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  7. Dermal Filler Do's and Don'ts for Wrinkles, Lips and More

    U.S. Food and Drug Administration (FDA) · 2026

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  8. Belotero Volume (+) Lidocaine — Prescribing Information and Instructions for Use

    FDA device labeling / Merz North America · 2026

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review